Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Low

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Alzheimer'S Research & Therapy|October 12, 2022
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia studyAudrey Low, Maria A Prats-Sedano, Elizabeth McKiernan, et al.
Nucleic Acids Research|April 30, 2019
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteinsMichael T Migawa, Wen Shen, W Brad Wan, et al.
Nature Communications|August 11, 2015
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingKazutaka Nishina, Wenying Piao, Kie Yoshida-Tanaka, et al.
Nature Biotechnology|May 1, 2019
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic indexWen Shen, Cheryl L De Hoyos, Michael T Migawa, et al.
Cerebral Circulation - Cognition and Behavior|January 19, 2026
The international society of vascular behavioural and cognitive disorders: highlights from VasCog 2025 in the UKAnna Marseglia, Roxana O Carare, Jessica L Teeling, et al.
Alzheimer'S Research & Therapy|August 7, 2025
Machine learning applications in vascular neuroimaging for the diagnosis and prognosis of cognitive impairment and dementia: a systematic review and meta-analysisValerie Lohner, Amanpreet Badhwar, Flavie E Detcheverry, et al.
Nucleic Acids Research|August 21, 2021
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotidesBrooke A Anderson, Graeme C Freestone, Audrey Low, et al.
Molecular Neurodegeneration|April 14, 2026
Regional diffusion imaging measures to disentangle SVD-related hypertensive arteriopathy versus cerebral amyloid angiopathySheelakumari Raghavan, Scott A Przybelski, Robel K Gebre, et al.
Nucleic Acids Research|July 5, 2014
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in miceThazha P Prakash, Mark J Graham, Jinghua Yu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 20, 2025
Associations of estrogen with modifiable and non-modifiable risk factors for dementia: A narrative reviewSarah Gregory, Katie Bridgeman, Hannah Darwin, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Alzheimer'S Research & Therapy|October 12, 2022
Modifiable and non-modifiable risk factors of dementia on midlife cerebral small vessel disease in cognitively healthy middle-aged adults: the PREVENT-Dementia studyAudrey Low, Maria A Prats-Sedano, Elizabeth McKiernan, et al.
Nucleic Acids Research|April 30, 2019
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteinsMichael T Migawa, Wen Shen, W Brad Wan, et al.
Nature Communications|August 11, 2015
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingKazutaka Nishina, Wenying Piao, Kie Yoshida-Tanaka, et al.
Nature Biotechnology|May 1, 2019
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic indexWen Shen, Cheryl L De Hoyos, Michael T Migawa, et al.
Cerebral Circulation - Cognition and Behavior|January 19, 2026
The international society of vascular behavioural and cognitive disorders: highlights from VasCog 2025 in the UKAnna Marseglia, Roxana O Carare, Jessica L Teeling, et al.
Alzheimer'S Research & Therapy|August 7, 2025
Machine learning applications in vascular neuroimaging for the diagnosis and prognosis of cognitive impairment and dementia: a systematic review and meta-analysisValerie Lohner, Amanpreet Badhwar, Flavie E Detcheverry, et al.
Nucleic Acids Research|August 21, 2021
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotidesBrooke A Anderson, Graeme C Freestone, Audrey Low, et al.
Molecular Neurodegeneration|April 14, 2026
Regional diffusion imaging measures to disentangle SVD-related hypertensive arteriopathy versus cerebral amyloid angiopathySheelakumari Raghavan, Scott A Przybelski, Robel K Gebre, et al.
Nucleic Acids Research|July 5, 2014
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in miceThazha P Prakash, Mark J Graham, Jinghua Yu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 20, 2025
Associations of estrogen with modifiable and non-modifiable risk factors for dementia: A narrative reviewSarah Gregory, Katie Bridgeman, Hannah Darwin, et al.
Pageof 7